Board of Directors
Lequn Lee Huang
President, CEO and Director
Dr. Lequn Lee Huang is the President, CEO, Treasurer and a director of the company. Dr. Huang was one of the founders of Dong Ying China and has been the Chairman, CEO, and a director of Dong Ying China since 2004. Since 2004, Dr. Huang has been a professor at the Medical School at Nanjing University. From 1991 to 2004, Dr. Huang worked at the Bayer Research Center in New Haven, Conn., U.S., for Bayer Co. where he became the Principal Research Scientist and Head of the MS Lab. At the Bayer Research Center, Dr. Huang’s group was responsible for analysis of drug discovery. In 1981, Dr. Huang received his B.S. in Organic Chemistry from Nanjing University in China and, in 1987, he received his Ph.D. in Analytical Chemistry from Iowa State University. Dr. Huang is not an officer or director of any other reporting issuer.
Xuejun Chen
Senior Vice President & Director
Mr. Xuejun Chen is the Senior Vice President and a director of the company. Since 2006, Mr. Chen has been the Executive Vice President of Sales, and a director of Dong Ying China where he is responsible for sales. From 2005 to 2006, Mr. Chen was the Vice President of Sales for Nanjing Langkun Medicine Co., Ltd. From 2004 to 2005, Mr. Chen was the Marketing Director for the Province of Jiangsu for Medicine Co., Ltd. From 2003 to 2004, Mr. Chen was the Sales director for the Province of Jiangsu for Xiamen Beidazhilu Biotech Co., Ltd. In the first two of these pharmaceutical companies, he was responsible for sales, and in the latter, for regional sales. In 1998 Mr. Chen received his B.S. from Lanzhou University in China, and in 2007 he received his M.B.A from Nanjing University. Mr. Chen is not an officer or director of any other reporting issuer.
Xinjie Mu
CFO, Director
Mr. Xinjie (James) Mu was an independent consultant from January 2008 to September 2009 and has been the CFO since September 2009. From March 2008 to June 2010, Mr. Mu was a director of China Infrastructure Investment Corporation (NASDAQ: CIIC). From April 2007 to December 2007, Mr. Mu was the Chief Financial Officer of Jingwei International Limited (OTCBB: JNGW.OB). From January 2006 to April 2007, Mr. Mu served as the Senior Accountant for Geller and Company. From September 1999 to March 2005, Mr. Mu served as the Senior Accountant of Flightsafety International, Inc., a wholly-owned subsidiary of Berkshire Hathaway. Mr. Mu earned his B.S. at Hebei University of Science and Technology (Chemical Engineering) in 1992 and his MBA at Baruch College of the City University of New York in 1997. Mr. Mu received his CPA designation from the state of Maryland in 1997.
Yuanwei Chen
Director
Dr. Yuanwei Chen is a director of the company. Since March, 2008, Dr. Chen has been the General Manager of China Gateway Pharma Products (Chengdu) Co. Ltd., and the Vice President of Medicinal Chemistry of Shanghai ChemPartner Co., both of which are in pharmaceutical research. As the Vice President of Medicinal Chemistry of Shanghai ChemPartner Co., Dr. Chen is responsible for managing the operations of his department, allocating resources, managing projects and recruiting employees. From February 2005 to March 2008, Dr. Chen was the Chief Scientific Officer of Egret Pharma (Shanghai) Ltd. in Shanghai, China where he was responsible for establishing the company’s drug discovery platform, the company’s research strategy, managing finances, and recruiting employees. From December 1998 to February 2005, Dr. Chen worked with Bayer Healthcare in West Haven, Connecticut, U.S. At Bayer Healthcare, Mr. Chen worked in the Pharmaceutical Division as a Senior Research Scientist I, Senior Research Scientist II, and as a Senior lab head. As a Senior lab head, Dr. Chen was responsible for proposing and implementing research and development strategies for various projects, and supervising and training research staff. In 1983, Dr. Chen received his B.S. in Organic Chemistry, and in 1986 he received his M.S. in Organic Chemistry from Sichuan University in China. In 1993 Mr. Chen received his PhD. in Organic Chemistry from the University Lausanne in Switzerland, and in 1995 he completed his Postdoctoral Fellowship with the Scripps Research Institute in La Jolla, California, U.S. Dr. Chen is not an officer or director of any other reporting issuer.
Du Wang
Independent Director
Dr. Du Wang has been a private investor since 2000. His major accomplishments include founding the first non-performing loan (NPL) investment fund in China. From 1998 until 2000 he was president of JP Morgan Chase Hong Kong. Previously, from 1997 until 1998, he managed Smith Investments, a distressed asset investment fund based in New York. Dr. Du Wang was also a fund manager at Princeton Capital Management, a New York security investment fund, from 1991 to 1997. He received his PhD in Economics from the State University of New York (SUNY) at Stony Brook and holds a Masters in Management from Stevens Institute of Technology in New Jersey. He received a Bachelor's Degree in Business Administration from Tianjin University in China.
Eric Shi
Independent Director
Dr. Eric Shi founded DiereTech Bio-Pharma, Inc. in 2009. DiereTech Bio-Pharma focuses on developing new drugs for the China market. Prior to founding DiereTech Bio-Pharma, in 2004, Dr. Shi incorporated DiereTech Investment Limited, Inc., a Hong Kong company engaged in investing in new drug projects in China and in European countries. In 2005, Dr. Shi incorporated DierePharma, Inc. in New York. DierePharma conducts deep research and development on drugs with IP obtained by DiereTech Investment Limited. In 2006, Mr. Shi incorporated Beijing Unimedex Science & Technology Development Co., Ltd., a company located in Beijing and currently conducting research on medical apparatus and instruments for urine control. Dr. Shi was the Chief Professor at the Long Island Jewish Medical Center Department of Radiation beginning in 2004. Prior to that, from 1994 to 2003, Dr. Shi was Associate Professor at Albert Einstein College of Medicine. In 1993, Dr. Shi received his post-doctorate training from Georgetown University Cancer Research Center and earned his PhD in Biochemistry from Dartmouth Medical School in 1989. He received his Bachelor’s degree from Beijing University in 1983.